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 First human disease with mutation of a Wallerian degeneration pathway gene 
 NMNAT2 homozygous loss-of-function in polyneuropathy with erythromelalgia 
 Loss of myelinated and unmyelinated fibers and of sensory and motor amplitude 
 Mutation lowers thermal stability and greatly increases Km for substrate NMN 
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We	 identified	 a	 homozygous	 missense	 mutation	 in	 the	 gene	 encoding	 NAD	 synthesizing	 enzyme	





















Erythromelalgia	 is	a	 rare	clinical	syndrome	characterized	by	 intermittent	attacks	of	 intense	burning	
pain	with	redness	and	swelling	predominantly	affecting	the	lower	extremities	but	which	may	also	be	
present	 in	 upper	 extremities.	 It	was	 named	by	 S.	Weir	Mitchell	 in	 1878	 from	erythro	 (red),	melos	
(extremity),	 and	 algos	 (pain)	 (Mitchell,	 1878).	 The	 episodes	 can	 be	 induced	 by	 heat,	 exercise	 and	
gravity	and	can	be	relieved	by	cooling	and	elevation.	They	usually	have	their	onset	in	the	first	decade	
but	may	also	first	appear	during	adulthood.	Erythromelalgia	can	be	classified	as	primary	or	secondary.	
In	 a	 population-based	 study	 from	Minnesota,	 the	 incidence	of	 erythromelalgia	 overall	was	 1.3	per	
100,000	people	per	year	with	a	preponderance	of	primary	erythromelalgia	(1.1	per	100,000	people	
per	year)	(Reed	and	Davis,	2009).	Secondary	erythromelalgia	can	occur	in	a	number	of	disorders	like	
small	 fiber	 peripheral	 neuropathies,	 thrombocythemia,	 myeloproliferative	 diseases,	 as	 a	
paraneoplastic	 syndrome	or	as	a	side	effect	of	different	medications	 (Layzer,	2001).	Many	patients	
affected	with	primary	erythromelalgia	carry	gain-of-function	mutations	in	the	SCN9A	gene	coding	for	





with	 erythromelalgia.	 Sequencing	 of	 the	 complete	 coding	 region	 of	 SCN9A	 did	 not	 reveal	 any	
mutations.	 We	 therefore	 proceeded	 to	 exome	 sequencing	 in	 both	 sisters	 and	 the	 parents	 and	
discovered	 a	 homozygous	mutation	 in	NMNAT2	 in	 the	 patients	 and	heterozygosity	 in	 the	 parents.	
















used	 to	mark	duplicated	reads,	 to	do	a	 local	 realignment	around	short	 insertions	and	deletions,	 to	
recalibrate	 the	 base	 quality	 scores	 and	 to	 call	 SNPs	 and	 short	 Indels.	 The	GATK	UnifiedGenotyper	
variation	calls	were	filtered	for	high-quality	(DP>15;	AF>0.25;	QD>2;	MQ>40;	FS<60;	MQRankSum>-
12.5;	 ReadPosRankSum>-8;	HaplotypeScore	 <13)	 rare	 (MAF	≤	 0.005	based	on	1000	 genomes	build	
20110521	 and	 EVS	 build	 ESP6500	 and	 the	 Exome	 Aggregation	 Consortium	
(http://exac.broadinstitute.org/))	 variants,	 predicted	 to	 modify	 a	 protein	 sequence	 or	 to	 impair	
splicing,	implicated	by	reduced	maximum	entropy	scores	(MaxEntScan).	False	positive	and	irrelevant	
variants	were	further	reduced	by	taking	advantage	of	the	Varbank	InHouseDB	containing	511	epilepsy	
exomes.	 Compound	 heterozygous	 and	 homozygous/hemizygous	 variants	 were	 extracted	 for	 the	
patient.	 Prediction	 of	 functional	 impact	 of	 all	 received	 variants	 was	 performed	 using	 the	 dbNSFP	
version	 3.0a36,37.	 DbNSFP	 software	 co-applied	 several	 in	 silico	 analysis	 tools	 to	 predict	 the	
conservation,	 using	 PhastCons	 and	 GERP,	 and	 the	 functional	 consequence,	 using	 SIFT,	 PolyPhen2,	
Provean,	 LRT,	 MutationTaster,	 MutationAssessor,	 FATHMM,	 VEST,	 MetaSVM	 and	 MetaLR,	 of	 the	
affected	site.	 In	addition	phenotype	genotype	correlations	were	 investigated	using	public	database	
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CCT	 CCT	 CCT	 TTG-3’.	 Gel	 electrophoresis	 was	 performed	 using	 a	 1%	 agarose	 gel.	 For	 sequencing,	
specific	bands	were	eluted	from	the	gel	by	use	of	NucleoSpin®	Gel	and	PCR	Clean-up	(Machery-Nagel,	
Düren,	 Germany)	 and	 subsequently	 processed	 for	 direct	 dye	 terminator	 sequencing	 with	 BigDye	




Constructs.	 NMNAT2	 T94M	 and	 H24D	 mutations	 were	 introduced	 by	 QuikChangeII	 site-directed	
mutagenesis	(Stratagene)	into	the	complete	open	reading	frame	(ORF)	of	the	canonical	307	amino	acid	
human	 NMNAT2	 variant	 (NCBI ProteinID: NP_055854) cloned	 in	 expression	 vector	 pCMV	 Tag-2B	
(Stratagene).	 A	 short	 linker	 (17	 amino	 acids)	 is	 present	 between	 and	 N-terminal	 tag	 Flag	 and	 the	
NMNAT2	ORF.	DNA	 sequencing	 (Cogenics)	 confirmed	 the	presence	of	 the	 T94M	mutation	 and	 the	
absence	 of	 PCR	 errors.	 The	 wild-type	 or	 T94M	 mutant	 ORFs	 were	 then	 PCR-cloned	 into	 pET28c	
(Novagen)	 for	 bacterial	 production	 of	 the	 proteins	 with	 an	 N-terminal	 6x	 His	 tag.	 pDsRed2-N1	







Microinjection,	 transection	of	neurites	and	 imaging.	Dissociated	SCG	neuron	cultures	 (from	P0-P2	








images	 captured	 with	 a	 4x	 objective	 using	 Fiji	 software	 http://fiji.sc	 (Schindelin	 et	 al.,	 2012)	 by	





sodium	pyruvate	 (PAA),	 supplemented	with	2	mM	glutamine	and	1%	penicillin/streptomycin	 (both	
Invitrogen),	 and	 10%	 fetal	 bovine	 serum.	 Cells	 were	 plated	 in	 24-well	 format	 to	 reach	 50-60%	
confluence	 before	 transfection	 with	 Lipofectamine	 2000	 reagent	 (Invitrogen)	 according	 to	 the	
manufacturer’s	instructions.	500	ng	Flag-NMNAT2	expression	vector	(wild-type	or	T94M),	200	ng	of	an	
empty	 pCMV-Tag	 series	 vector,	 and	 100	 ng	 pEGFP-C1	 were	 transfected	 per	 well.	 10	 µM	 emetine	
hydrochloride	 (Sigma-Aldrich)	was	 used	 to	 block	 protein	 synthesis.	 Cells	 from	 single	wells	 at	 each	
timepoint	 after	 treatment	 were	 lysed	 directly	 in	 100	 µl	 2x	 Laemmli	 sample	 buffer,	 sonicated	 to	
fragment	genomic	DNA	in	the	absence	of	heating,	and	equal	amounts	(10µl)	used	for	immunoblotting.	
	
Immunoblotting.	 Extracts	were	 resolved	on	4-15	or	4-20%	SDS	polyacrylamide	gels,	 transferred	 to	






West	 Dura	 Extended	 Duration	 Substrate	 (Thermo	 Fisher	 Scientific)	 using	 an	 Alliance	
chemiluminescence	imaging	system	(UVITEC	Cambridge).	Relative	band	intensities	on	captured	digital	





tag:	MGSSHHHHHHSSGLVPRGSH.	 Expression	was	 carried	out	 into	E.	 coli	 BL21(D3)	 cells	 (Invitrogen)	
following	 0.5	 mM	 IPTG	 induction	 for	 17h	 at	 28	 °C	 and	 purification	 by	 TALON	 chromatography	
(Clontech),	 essentially	 as	 described	 (Orsomando	 et	 al.,	 2012).	 The	 purified	 proteins	 were	 finally	
desalted	 on	 PD-10	 columns	 (GE	 Healthcare)	 in	 50	mM	HEPES/NaOH	 buffer,	 pH	 7.5,	 1	mM	 Tris(2-
carboxyethyl)phosphine	(TCEP),	20	%	glycerol,	and	stored	at	-80	°C.	Their	concentration	was	measured	
by	the	Bio-Rad	protein	assay.	Their	purity	was	evaluated	on	12%	SDS	polyacrylamide	gels	either	by	
Coomassie	 staining	 or	 after	 immunoblotting	 as	 described	 above,	 using	 monoclonal	 anti-NMNAT2	
(1:1,000	Abcam	Ab5698)	as	the	primary	antibodies.	
	
Activity	 assays.	 One	 unit	 (U)	 of	 NMNAT	 activity	 is	 defined	 as	 the	 enzyme	 amount	 catalyzing	 1	
µmol/min	product	formation	at	the	indicated	temperature.	Rates	were	routinely	measured	at	37	°C	by	
a	 spectrophotometric	 coupled	 assay	 (Balducci	 et	 al.,	 1995),	 unless	 otherwise	 indicated,	 in	 0.5	mL	
mixtures	containing	30	mM	HEPES/NaOH	buffer,	pH	7.5,	0.5	mg/mL	bovine	serum	albumin	(BSA	Sigma-
Aldrich	 A7906),	 75	 mM	 ethanol,	 30	 mM	 semicarbazide	 (Sigma-Aldrich	 S2201),	 12.5	 U/mL	 alcohol	
dehydrogenase	(ADH	Sigma-Aldrich	A7011).	The	wild	type	NMNAT2	was	added	at	0.2-0.8	μg/mL	in	the	
presence	of	25	mM	MgCl2	and	1	mM	both	ATP	and	NMN.	The	T94M	mutant	was	added	at	0.5-1.5	




























was	 normal	 (sitting	 6	 months,	 walking	 11	 months,	 first	 words	 12	 months).	 At	 age	 4	 years	 she	








trial	 with	 colchicine	 had	 no	 effect,	 but	 steroids	 seemed	 to	 shorten	 the	 attacks.	 In	 addition,	 she	
presented	with	bilateral	pes	cavus	and	pes	equinus	and	a	mild	tremor	of	both	hands	(Fig.	1).	Other	





















or	 infections.	Overall	she	was	 less	affected	than	her	sister	and	with	time	the	episodes	became	 less	
severe.	Physical	examination	at	age	16	showed	pes	cavus	and	pes	equinus.	Electrophysiology	showed	




After	genetic	analysis	of	 the	SCN9A	 gene	did	not	 reveal	 any	abnormalities,	exome	sequencing	was	
performed.	Nonsynonymous,	 homozygous	 variants	 in	 4	 genes,	TGFB1I1	 (c.454C>T,	 p.R152C),	AHSP	
(c.224A>T,	p.N75I,	rs75782426),	LAMC1	(c.923A>G,	p.K308R,	rs139092535)	and	NMNAT2	(c.281C>T,	
p.T94M)	were	detected	in	both	affected	sisters.	The	variants	in	the	AHSP	and	LAMC1	genes	have	been	
described	 previously	 with	 an	 allele	 frequency	 of	 0.0047	 (including	 5	 homozygous	 individuals)	 and	

















affected	 sisters	 were	 homozygous	 (Fig	 3).	 We	 established	 a	 cohort	 of	 87	 patients	 suffering	 from	
erythromelalgia	coming	from	Germany	or	the	Netherlands.	DNA	was	obtained	from	these	patients	and	




T94M	 NMNAT2	 has	 reduced	 capacity	 to	 promote	 neurite	 survival	 that	 is	 partly	 temperature-
dependent	
To	test	whether	the	homozygous	NMNAT2	mutation	in	these	siblings	could	be	the	underlying	cause	of	




differentiate	 the	 axon-protective	 competence	 of	 NMNAT	 proteins,	 including	 a	 variety	 of	 artificial	
NMNAT2	mutants	(Gilley	and	Coleman,	2010;	Milde	et	al.,	2013).	
	 12	









at	 39°C	 (Fig.	 4A	 and	 4B).	 In	 contrast,	 H24D	 Flag-NMNAT2	 conferred	 no	 protection	 at	 either	
temperature,	as	expected	for	an	NMNAT2	protein	lacking	enzymatic	activity	(Milde	et	al.,	2013;	Yan	et	
al.,	2010).	Crucially,	while	expression	 level	can	strongly	 influence	protective	capacity	 in	this	type	of	
experiment,	Flag	immunostaining	revealed	that	T94M	Flag-NMNAT2	expression	broadly	matches	that	
of	wild-type	Flag-NMNAT2	in	injected	neurons	(Fig.	4C).	
The	above	experiments	were	performed	 in	 the	presence	of	endogenous,	murine	NMNAT2,	but	 the	
affected	 siblings,	 homozygous	 for	 the	 NMNAT2	 mutation,	 should	 only	 express	 T94M	 NMNAT2.	
Therefore,	we	next	assessed	whether	 the	presence	of	endogenous	NMNAT2	might	mask	a	greater	
difference	in	protective	capacity	of	wild-type	and	T94M	Flag-NMNAT2	by	performing	the	same	neurite	
transection	 assay	 (at	 37°C)	 in	 NMNAT2-deficient	 neurons.	 Neurons	 lacking	 NMNAT2	 alone	
(Nmnat2gtE/gtE	 neurons)	 are	 unsuitable	 for	 this	 due	 to	 their	 severely	 stunted	 neurites	 (Gilley	 et	 al.,	
2013),	 but	 NMNAT2-deficient	 neurons	 additionally	 lacking	 the	 pro-degenerative	 protein	 SARM1	
(Nmnat2gtE/gtE;Sarm1-/-	 neurons)	 grow	 normally	 and	 the	 inherent	 resistance	 of	 their	 neurites	 to	
degeneration	can	be	overcome	by	SARM1	re-expression	(Gilley	et	al.,	2015).	NMNAT2	enzyme	activity	
is	required	for	survival	of	intact	neurites	when	SARM1	is	present	(Gilley	et	al.,	2015)	and,	consistent	
with	 this,	 we	 found	 that	 the	 majority	 of	 (uninjured)	 neurites	 of	 Nmnat2gtE/gtE;Sarm1-/-	 neurons	




functional	 NMNAT2,	 although,	 notably,	 survival	was	 consistently	 slightly	 reduced	 compared	 to	 co-
injection	 with	 wild-type	 Flag-NMNAT2	 and	 SARM1(-GFP)	 vectors	 (Fig.	 4D).	 Furthermore,	 we	
subsequently	 found	 that	 T94M	 Flag-NMNAT2	 was	 significantly	 less	 able	 to	 protect	 neurites	 after	
transection	in	this	context	(no	endogenous	NMNAT2)	than	in	wild-type	neurons	(Fig.	4A	and	4E).		







Loss	 of	 stability	 or	 loss	 of	 enzymatic	 activity	 are	 possible	 alternative	 explanations	 for	 the	 reduced	













of	 wild-type	 Flag-NMNAT2	 at	 39°C	 closely	 matches	 that	 of	 T94M	 Flag-NMNAT2	 at	 37°C	 (Fig.	 5C).	
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Intriguingly,	 this	 overlap	 between	 decay	 curves	 mirrors	 the	 similarity	 in	 the	 degree	 of	 protection	
conferred	to	cut	neurites	by	wild-type	Flag-NMNAT2	at	37°C	and	T94M	Flag-NMNAT2	at	39°C	(Fig.	4A).	
As	well	as	potentially	making	NMNAT2	inherently	less	stable,	the	T94M	substitution	also	substantially	
increases	 the	 rate	 of	 turnover	 of	 the	 protein	 in	 cells.	 Accelerated	 loss	 of	 T94M	 NMNAT2	 after	















from	 the	 mutation.	 First,	 we	 observed	 a	 difference	 in	 Mg2+-dependence.	 Both	 enzymes	 showed	
optimum	activity	at	~1	mM	Mg2+,	as	previously	reported	(Sorci	et	al.,	2007),	but	the	mutant,	unlike	the	















time-dependent	 fluctuation	 of	 Nam,	 NMN	 and	 NAD	 levels.	 As	 predicted,	 there	 was	 greater	
accumulation	 of	 NMN	with	 T94M	 NMNAT2	 than	 with	 the	 wild-type	 enzyme	 (~50	µM	 vs	 ~10	µM	
respectively),	along	with	a	trend	towards	lower	NAD	(~	280	µM	vs	~350	µM)	that	may	also	contribute	
to	axon	vulnerability	(Fig.	7).	
The	 effect	 of	 temperature	 on	 the	 activity	 of	 the	 purified	 wild-type	 and	 T94M	 enzymes	 was	 also	
evaluated	(Fig.	8).	T94M	NMNAT2	was	slightly	more	prone	to	inactivation	at	a	range	of	temperatures	
(Fig.	8A)	and	its	activity	had	a	significantly	reduced	half-life	relative	to	wild	type	NMNAT2	at	37	°C	(Fig.	























its	 candidacy	 as	 the	 underlying	 cause	 of	 the	 polyneuropathy	 with	 erythromelalgia	 in	 the	 affected	





for	 both	 its	 enzyme	 and	 axon	 survival	 functions	 (Figs	 4	 and	 8)	 provide	 good	 explanations	 for	 how	





NMNAT2	 is	 to	 date	 the	 only	 mammalian	 isoform	 without	 a	 defined	 3D	 structure	 but	 sequence	
alignment	with	 other	NMNATs	 indicates	 that	 T94	 in	 human	NMNAT2	 is	 flanked	 by	 two	 conserved	
residues	 involved	 in	pyridine	nucleotide	binding,	 corresponding	 to	W92	and	T95	 (Rodionova	et	al.,	
2015;	 Zhou	 et	 al.,	 2002).	 However,	 a	 T94	 equivalent	 is	 not	 conserved	 in	 other	 NMNATs	 so	 its	
importance	for	substrate	interaction	was	previously	unclear.	The	change	in	substrate	affinity	of	human	
T94M	NMNAT2	suggests	T94	is	either	directly	involved	in	substrate	interaction	or	that	the	amino	acid	
substitution	 interferes	 with	 substrate	 binding	 to	 nearby	 residues.	 Altered	 thermal	 stability	 of	 the	
mutant	protein	also	suggests	an	important	role	for	this	residue	in	protein	folding.		
All	previous	data	on	NMNAT2	mutant	phenotypes	come	from	mouse	studies	where	expression	is	either	




Intriguingly,	 there	 are	 strong	 parallels	 between	 the	 patients	 described	 here	 and	 mice	 with	 sub-
heterozygous	 levels	 of	 NMNAT2.	 Specifically,	 both	 have	 a	 clear,	 early-onset	 sensory	 phenotype	
involving	 loss	of	myelinated	sensory	axons	 in	peripheral	nerves	and	altered	 temperature	 sensation	
(Gilley	 et	 al.,	 2019).	 The	 absence	 of	 this	 phenotype	 in	 mice	 with	 heterozygous	 NMNAT2	 levels	
outwardly	suggests	 that	episodes	of	erythromelalgia	 in	 the	patients	 requires	 reduction	 in	NMNAT2	
activity	 to	sub-heterozygous	 levels.	However,	 the	greater	 length	of	human	axons	could	make	them	
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not	 significant	 (p	 >	 0.05),	 **	 p	 <	 0.01,	 ***	 p	 <	 0.001,	 two-way	 ANOVA	 with	 Tukey’s	 multiple	
comparisons	test.	(B) Representative	images	of	assays	performed	at	39°C	as	described	in	A. Images	
show	transected	neurites	at	0	and	24	hours	after	cut	with	the	lesion	site	located	just	below	the	bottom	
edge	of	 the	 field.	Brightness	and	contrast	have	been	adjusted	to	optimize	neurite	visualization. (C)	
	 24	
Relative	 expression	 of	 wild-type	 (WT)	 or	 T94M	 Flag-NMNAT2	 in	 injected	 SCG	 neuron	 cell	 bodies.	
Representative	 fluorescent	 images	 are	 shown	 of	 SCG	 neurons	 48	 hours	 after	 co-injection	 with	
expression	vectors	for	WT	or	T94M	Flag-NMNAT2	(10	ng/µl)	and	DsRed	(50	ng/µl);	DsRed	identifies	
injected	neurons,	Flag	immunostaining	shows	expression	of	the	Flag-NMNAT2	proteins,	DAPI	labels	all	
nuclei.	 Relative	 intensities	 (±	 SEM)	 of	 Flag	 immunostaining	 and	 DsRed	 signal	 are	 shown	 after	
transformation	to	the	mean	of	levels	in	neurons	injected	with	the	wild-type	Flag-NMNAT2	construct.	
WT	and	T94M	data	was	calculated	from	41	and	43	injected	neurons	(DsRed	positive)	of	which	65.9%	


















mix	 (see	 Materials	 and	 Methods).	 Co-transfected	 eGFP	 and	 endogenous	 a-Tubulin	 (present	 in	









fitted	 to	each	data	 set	using	non-linear	 regression.	R2	value	and	half-life	 (t½)	are	 reported	 for	each	
curve.	 Statistical	 comparisons	 are	 shown	 on	 the	 right	 (two-way	 ANOVA	 with	 Tukey’s	 multiple	
comparisons	test	for	effects	between	variants).	
	
Figure 6. SDS-PAGE, immunoblotting and Mg2+-dependence of WT and T94M NMNAT2. (A) 
Coomassie blue stained 12 % polyacrylamide gel after running of ~2 µg each purified protein species. 
(B) Membrane-immobilized proteins after probing with monoclonal anti-NMNAT2 and 
chemiluminescence imaging. (C) Magnesium-dependent changes of rates (mean ± SEM from n = 4) 
referred to the value at 5 mM MgCl2 (arbitrary 100%). T test p values (*) for T94M vs WT: 0.037 at 20 
mM MgCl2, 0.006 at 50 mM MgCl2, and 0.009 at 100 mM MgCl2. 
	
Figure 7. Accumulation of the NMN intermediate in NAMPT-NMNAT2 coupled reactions: 
comparison between WT and T94M NMNAT2. In vitro HPLC assays after coupling a pure recombinant 
murine NAMPT to either WT or T94M mutant human NMNAT2. The NAD biosynthesis starts from Nam 
(nicotinamide) and PPase (inorganic pyrophosphatase) was added to prevent the reverse reactions (see 
the top scheme). Data represent mean ± SD of 2 independent experiments. The two time-course 
analyses show, under similar NAD synthesis rates, a higher transient accumulation of the NMN 
intermediate in the T94M mutant. 
 
Figure 8. Temperature studies of WT and T94M NMNAT2. Data represent mean ± SEM of n 
experiments as indicated. (A) Apo-enzymes’ stability at different temperatures. Buffered enzyme 
solutions (40 µg/ml hNMNAT2 WT or 30 µg/ml T94M mutant in 50 mM HEPES/NaOH buffer, pH 7.5, 1 
	 26	
mM TCEP, 20 % glycerol) were pre-incubated for 1 hour at the indicated temperatures, then assayed 
at 37 °C. Values (n = 6) are referred to the untreated enzyme kept at +4 °C (arbitrary 100%). (B) Apo-
enzymes’ stability at 37 °C. Enzyme solutions were incubated and collected at the indicated time 
intervals, then assayed at 37 °C. Values (n = 4) are referred to that of time zero (arbitrary 100%). T test 
p values (*) for T94M vs WT: 0.013 at 8 min, 0.010 at 14 min, 0.013 at 20 min, and 0.014 at 28 min. (C) 
Enzymes’ stability at 37 °C in the presence of substrates. Enzyme solutions supplied with 100 µM both 
NMN and ATP were treated and assayed as in panel B. (D) Optimal temperature. Enzyme rates were 
measured after warming the assay mixtures at the indicated temperatures. Values (n = 4) are referred 
to the relative maximal rate observed for each enzyme (arbitrary 100%). After this assay, the mixtures 
at 47 °C were rapidly cooled down to 37 °C then new NMNAT2 aliquots were added and rates measured 
again, demonstrating full recovery of the original activity. This excludes any effect caused by heating on 















ATP 169.4 ± 45.5 8.40 ± 2.92 0.65 * 105 
NMN 38.0 ± 6.75 8.40 ± 2.92 2.36 * 105 
NMNAT2 T94M 
ATP 286.6 ± 32.9 9.20 ± 3.80 0.31 * 105 
NMN 256.8 ± 36.7 (*) 9.20 ± 3.80 0.35 * 105 
Data represent Mean ± SEM of 3 independent experiments. 



























































Rel. intensity: 1.00 ±0.14 0.86 ±0.08












































































































































(R2 = 0.975, t½ = 1.36)
WT 39
(R2 = 0.994, t½ = 0.61)
T94M 39
(R2 = 0.999, t½ = 0.33)
T94M 37
(R2 = 0.986, t½ = 0.54)
WT 37°C v T94M 37°C 
1 h p < 0.0001 *** 
2 h p = 0.0027 ** 
4 h p = 0.9997 n.s. 
WT 39°C v T94M 39°C 
1 h p = 0.0002 *** 
2 h p = 0.4026 n.s. 
4 h p > 0.9999 n.s. 
WT 37°C v WT 39°C 
1 h p < 0.0001 *** 
2 h p = 0.0017 ** 
4 h p = 0.9466 n.s. 
T94M 37°C v T94M 39°C 
1 h p = 0.0010 *** 
2 h p = 0.3098 n.s. 





































































































































































































































































































Affinity of human NMNAT2 WT and T94M for the alternative pyridine substrate NaMN.
Upper panels, primary plots of initial rates measured at variable NaMN and fixed 250 µM ATP.
Lower panels, the corresponding Lineweaver-Burk plots.
Supplemental Figure 1
